Safety Information

Varenzin-CA1 should not be administered to cats with known hypersensitivity to molidustat or to any of the inactive ingredients. Varenzin-CA1 should not be administered to cats that are pregnant, lactating, or intended for breeding.1

Warnings 

Keep Varenzin-CA1 in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.1

Human Warnings

• Not for use in humans. Keep this drug, including used syringes, out of reach of children. Wash hands immediately after use and/or spillage. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Symptoms of exposure to molidustat may include the following: gastrointestinal effects (nausea, vomiting, diarrhea), blood and clotting effects (increases in reticulocytes, erythropoietin, and hemoglobin), dizziness, fainting, hypertension, changes in cardiac output and cardiac index, and increases in heart rate. Symptoms may not occur immediately; therefore, the exposed individual should be monitored.1
• People with known hypersensitivity to molidustat sodium should avoid direct contact with this product and should administer the product with caution. Women who are pregnant or may become pregnant should administer the product with caution. Molidustat administered orally to pregnant rats during the period of organogenesis was associated with adverse fetal outcomes. Do not eat, drink, or smoke while handling this product.1

References

1. Elanco. Varenzin-CA1 (Molidustat Oral Suspension) Safety Data Sheet. 2023, https://assets-us-01.kc-usercontent.com/e4748d51-2c24-00f7-fc54-65f3864ee8b1/34dea92e-ed76-4687-bf68-712553c503ae/PROMO_WEB_502023As_90203666_W2a_WS.pdf